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adult dog model, two 5-mm longitudinal tears were created in the
avascular portion of the medial meniscus. Each tear was treated
with one BioDuct® implant placed at the tear site (n=10), fol-
lowed by suture repair. After 16 weeks, both knees were assessed
for gross pathology, articular cartilage damage (India ink stain-
ing), and repair tissue appearance. Limbs were processed for 3T
MRI and histologic examination (n=4) or biomechanical evaluation
(n=6). MRI evaluation utilized a water-sensitive, moderate echo
time fast spin echo protocol previously applied clinically, with a
resolution of 175 μm by 187.5 μm by 1.2 mm. Meniscal healing
was made based on the presence or absence of ﬂuid inhibition
into the repair site as well as any discernible fragmentation.
Results: In vitro, the PLLA and 85/15 materials did not lose
mass throughout the study. The 50/50 and 10/90 samples began
to lose mass after 3 and 1 week, respectively and were almost
completely degraded by 7 weeks. The inherent viscosity of the
materials decreased more rapidly with increasing PGA content.
The 3-point bend and crush strength properties of the implants
were found to decrease with time, with the exception of PLLA.
Figure 1. Biomechanical strength of repaired tear.
In vivo, all of the BioDuct® implant groups provided function-
ally healed avascular meniscal tissue in the dogs, independent of
bioabsorbable polymer tested. Tear strengths of the repaired avas-
cular tissue acquired 35-58% of contralateral, unoperated tissue
(Fig. 1). Histological analysis showed evidence of tissue ingrowth
and guided tissue engineering through the lumen of the conduit
(Fig. 2). MRI analyses conﬁrmed healing in 6 out of 8 anterior
repairs and 7 out of 8 posterior repairs where the conduit was
used (Fig. 3). Mild to moderate synovitis and chondral defects not
necessarily associated with the use of the implant were observed
with MRI; however, these defects were not apparent at gross
necropsy via India ink staining.
Figure 2. Denovo tissue in BioDuct conduit
lumen.
Figure 3. Sagittal fast spin echo
MR demonstrates lack of ﬂuid
inhibition, suggesting healing.
Conclusions: This study demonstrated the success of BioDuct®
repair in enabling healing of avascular tear in a dog meniscus,
independent of the PLA/PGA materials tested.
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SPECIFIC FACTORS ARE ASSOCIATED WITH FAILURE OF
MENISCUS SUTURE REPAIR
W.G. Rodkey1, K.K. Briggs1, J.R. Steadman2
1Steadman Hawkins Res. Fndn., Vail, CO; 2Steadman Hawkins
Clinic, Vail, CO
Purpose: Meniscus repairs with sutures have become more com-
mon as the importance of preserving the meniscus has been
established. Studies have shown a high rate of repeat surgery,
but it is unclear what factors contribute to failure. The purpose
of this study was to determine what factors lead to failure of su-
ture meniscus repair. Failure was operationally deﬁned as repeat
surgery on the meniscus within 2 years of the repair.
Methods: Two hundred eighty-three (283) meniscus suture re-
pairs were performed by a single surgeon. The average patient
age was 31 years (range, 18 to 71). There were 177 males
and 106 females. All repairs were completed with an inside-out
suture technique. One hundred thirty-seven (137) had an ACL re-
construction and meniscus repair (93 concurrent reconstructions
and 44 two-staged ACL reconstructions). One hundred eighty-one
(181) medial menisci and 102 lateral menisci were repaired. Of the
medial repairs, 80% were in the posterior third of the meniscus,
11% in the middle third, 1% in the anterior third, and 8% extended
to all areas of the meniscus. Of the lateral meniscus repairs, 49%
were in the posterior third, 26% in the middle third, 22% in the
anterior third, and 3% extended to all areas.
Results: Twenty-eight (28) patients (10%) had required repeat
surgery on the repaired meniscus within the ﬁrst 2 years and were
considered failures. The average time to repeat meniscus surgery
was 12 months (range, 2.5 to 24 months).There were no differ-
ences based on age, gender or location. Thirteen percent (13%)
of medial repairs and 4% of lateral repairs failed (p=0.012). Me-
dial meniscus repairs failed signiﬁcantly earlier (5.6 months) than
lateral meniscus repairs (12.9 months) (p=0.001). For patients
who had ACL reconstruction and meniscus repair, factors associ-
ated with failure included age (failed age=22; non-failure age=29;
p=0.013), and concurrent ACL reconstruction (two-staged repair
failures=2%; concurrent repair failures=11%; p=0.04).
Conclusions: Failure of suture repair of the meniscus within the
ﬁrst two years following index repair is more likely to occur in
medial meniscus repairs and in young patients who had a repair
and concurrent ACL reconstruction.
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USING A CULTURE MODEL OF HUMAN TENOCYTES TO
INVESTIGATE THE EFFECTIVENESS OF TENDOACTIVE®
FOR THE PROPHYLAXIS AND TREATMENT OF
TENDINOPATHIES
A. Torrent1, R. Ruhí1, M. Cid2, C. Csaki3, M. Shakibaei3
1R&D Joint Care Dept., BIOIBERICA S.A., Palafolls (Barcelona),
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Spain; 3Musculoskeletal Res. Group, Inst. of Anatomy,
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Purpose: Tendons have a limited capacity for self-repair due to low
cell density and little mitotic activity. Pro-inﬂammatory cytokines
such as interleukin-1β (IL-1β) have been identiﬁed as the main
initiators of tendinopathies, stimulating inﬂammation, apoptosis
and extracellular matrix (ECM) degradation. The aim of this study
was to evaluate the potential of Tendoactive®, a nutraceutical
formulation that contains mucopolysaccharides, hydrolyzed type I
collagen and vitamin C, in an in vitro model of tendon inﬂammation.
Methods: In monolayer cultures, primary human tenocytes were
either treated with Tendoactive®, non-stimulated or stimulated with
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IL-1β, stimulated with IL-1β and Tendoactive® or pre-stimulated
with Tendoactive® followed by co-treatment with Tendoactive®
and IL-1β. Cell viability, adhesion, proliferation and the produc-
tion of ECM were analysed with light microscopy and transmis-
sion electron microscopy (TEM). Immunoﬂuorescence was used
to evaluate production of type I collagen, the main extracellu-
lar matrix protein produced by tenocytes. We also studied the
expression of the signal transduction and adhesion molecule β1-
integrin.Western Blotting (WB) was performed to evaluate the ex-
pression of apoptotic and inﬂammatory markers (metalloprotease-
1 (MMP-1), cyclooxygenase-2 (Cox-2) and caspase-3).
Results: Tendoactive® had a potent stimulatory effect on human
tenocyte proliferation and ECM production and was also able
to suppress the catabolic, apoptotic and inﬂammatory effects
induced by IL-1β in human tenocytes. This was demonstrated by
the suppression of IL-1β-induced expression of MMP-1, Cox-2 and
caspase-3 and up-regulation of type I collagen and β1-integrin.
Conclusions: The results presented suggest that this formulation
inhibits catabolic and inﬂammatory processes in an in vitro model
of tendonitis.Tendoactive® may therefore be used on prophylaxis
and treatment of tendinopathies to stimulate tendon healing, re-
generation and repair.
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EFFECTIVENESS OF TREATMENT OF TENDINITIS AND
PLANTAR FASCIITIS BY TENDOACTIVE™
F. Nadal1, T. Bové2, D. Sanchís3, D. Martinez-Puig4
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Purpose: To evaluate the effectiveness of Tendoactive™ adminis-
tration in the treatment of 3 different tendinopathies, such as epi-
condylitis, supraspinous tendinopathy, achilles tendinopathy and
plantar fasciitis.
Methods: Twenty patients with each clinical condition, clinically
and ecographically veriﬁed, were enrolled between October 2007
and March 2008 resulting in a total of eighty participants. Patients
were randomly assigned to either a study group (n = 10) or a
control group (n = 10). During 3 months all the patients received
between 20 and 30 rehabilitation sessions. In addition the study
group consumed 2.16g/d of Tendoactive™, a food supplement
containing collagen, mucopolysaccharides and vitamin C. Pain,
SF36 quality of life survey, as well as standardized functional
assessment were evaluated before and 1, 2 and 3 months after
treatment.
Results: The study group displayed a signiﬁcant pain reduction
(P<0.05) in all the subgroups except for the epicondylitis group.
Pain reduction was associated with an improvement of at least
one SF36 subscale in each subgroup (P<0.05). At the end of the
treatment a signiﬁcant improvement in the functional assessment
of the physiotherapist was reported for all the tendinopathies
(P<0.05).
Conclusions: Our results suggest that the use of Tendoactive™
for the management of tendinopathies and plantar fasciitis is safe
and effective, leading to a signiﬁcant reduction in pain and im-
proving the biomechamical properties of the joint, without adverse
effects.
Pain: Clinical and Pathophysiology
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A DOSE-DEPENDENT IMPACT OF A STANDARDIZED
POWDER MADE FROM HIPS OF A ROSE SUBSPECIES
(ROSA canina) ON WOMAC PAIN SCORES IN PATIENTS
WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE
K. Winther1, A.S. Hansen1, A. Kharazmi2
1Frederiksberg Hosp., Univ. of Copenhagen, Frederiksberg,
Copenhagen, Denmark; 2RigsHosp.et, Univ. of Copenhagen,
Copenhagen, Denmark
Purpose: A ﬁxed daily dose of ﬁve grams of a standardized
powder, made from hips of a Rose subspecies (Rosa canina),
produced using a standardized methodology by Hyben Vital, Den-
mark, has signiﬁcantly lowered symptom scores in patients with
osteoarthritis and shown anti-inﬂammatory properties. The aim of
the present study was to test whether there was any indication of
a dose dependent impact on the WOMAC pain score, from the
present rose hip powder, when evaluating a group of patients all
suffering from osteoarthritis of the hip and/or knee according to the
American College of Rheumatology criteria for the classiﬁcation of
osteoarthritis.
Methods: 52 patients, mean weight 78.3 kg (range 50 -122 kg),
were randomly allocated to either 3 month treatment with ﬁve
grams daily of encapsulated standardised rose hip powder, or ﬁve
grams of placebo. There were no signiﬁcant difference regarding
weight, sex, duration of the disease, educational background or
consumption of additional pain killers, when comparing the two
groups. WOMAC questionnaires were used throughout the study
and each patients noted his/hers daily consumption of rescue
medication in a diary. Data evaluation was based on intention
to treat (ITT). To search for a possible dose-dependency of the
present treatment, a non-parametric Spearman correlation test
was applied on the active treated group as well as the placebo
group.
Results: An overall reduction in WOMAC pain, WOMAC stiffness
and ADL function was observed as a result of active treatment
when compared to placebo (p<0.05). Moreover active treatment
resulted in a reduction in the consumption of rescue medica-
tion, as compared to the consumption observed during placebo
(p<0.05). There was a signiﬁcant negative correlation between
weight and reduction in pain score in the group treated with rose
hip (correlation coefﬁcient = - 0.39, p value = 0.019) after three
weeks treatment and (correlation coefﬁcient = - 0.41, p value =
0.014) after three months treatment. No negative correlation was
observed when a similar analysis was applied on placebo treated
patients. No signiﬁcant correlation to weight was observed when
evaluating changes in WOMAC stiffness or ADL function in any of
the two groups.
Conclusions: It is suggested that the present rose hip powder
reduces WOMAC scores and the consumption of rescue medica-
tion in patients suffering from osteoarthritis of the hip and/or knee.
Further more the present powder may act dose-dependently on
pain.
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COMPARISON OF SYNOVIAL B-ENDORPHIN LEVEL IN
AVASCULAR NECROSIS, RHEUMATOID ARTHRITIS AND
OSTEOARTHRITIS OF THE FEMORAL HEAD AND KNEE
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1Univ. of Szeged, Szeged, Hungary; 2Hosp.ler Brothers of St John
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Purpose: Avascular necrosis of the femoral head (AVN) is a
